Core Insights - Clearmind Medicine Inc. has filed a patent application in South Korea for its proprietary compound MEAI, aimed at treating depression, thereby enhancing its global intellectual property protection [1][2][4] - MEAI is a non-hallucinogenic neuroplastogen that modulates serotonin pathways and promotes neuroplasticity, offering a new therapeutic approach for major depressive disorder, which affects over 280 million people globally [3][4] - The company has a robust intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and expand its IP protection [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including depression and alcohol use disorder [1][5] - The company is preparing for the next stages of clinical development and commercialization of its non-hallucinogenic therapies, aiming to bring these treatments to patients worldwide [5][6]

Core Insights - Clearmind Medicine Inc. has announced a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction, enhancing its intellectual property portfolio [1][2][4] - Cocaine use disorder is a significant global health issue with no FDA-approved treatments, presenting a market opportunity projected to grow from $1.36 billion in 2025 to $2.03 billion by 2032 [2] - MEAI is designed to modulate serotonin and dopamine pathways, potentially offering a safer alternative to existing behavioral interventions for addiction [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health problems, including addiction [1][4] - The company currently holds nineteen patent families with 31 granted patents and plans to pursue additional patents to strengthen its intellectual property [5] Market Context - The global market for cocaine addiction treatment is experiencing urgent demand for new solutions, highlighting the potential impact of Clearmind's developments in this area [2][3]

Core Insights - Clearmind Medicine Inc. is advancing its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), with the last patient in the first cohort having received treatment [1][5] - The global alcohol-dependency treatment market is projected to grow from approximately $13.2 billion in 2024 to about $20 billion by 2032, indicating a significant unmet need for effective treatments [4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address major health issues, including AUD [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to expand its intellectual property [7] Clinical Trial Details - The Phase I/IIa trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - The trial includes six patients treated at prestigious institutions like Johns Hopkins University and Yale School of Medicine, with additional sites activated in Israel [2][3] Market Opportunity - The urgent need for more effective AUD treatments is highlighted by the projected growth of the treatment market, emphasizing the commercial potential for new therapeutic approaches [4]

Core Insights - Clearmind Medicine Inc. is participating in a webinar focused on women in psychedelic leadership, highlighting its commitment to advancing psychedelic medicine [1][2] - The CEO, Dr. Adi Zuloff-Shani, will share insights on the company's strategic direction and the broader psychedelic landscape [2][3] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel neuroplastogen-derived therapeutics for under-treated health issues, including alcohol use disorder, cocaine addiction, and obesity [1][4] - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as needed [5] Event Details - The webinar titled "Women in Psychedelic Leadership: Driving Innovation & Governance" is scheduled for October 29, 2025, at 9:00 AM PT/noon ET, and will be accessible online [1][2][3] - Registration for the event is available through Eventbrite, inviting investors, researchers, and stakeholders to participate [3]

Core Insights - Clearmind Medicine Inc. has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance US partnerships and regulatory advocacy in the psychedelic medicine sector [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogens-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of 19 patent families with 31 granted patents and aims to expand this portfolio opportunistically [5] Leadership and Expertise - Mary-Elizabeth Gifford previously served as Chief of Global Impact at Psyence BioMed and has extensive experience in psychedelic policies and regulatory landscapes [2][3] - Gifford has been recognized as a significant figure in the psychedelic industry, being named a "Psychedelic Titan" and described as "the most quietly influential woman working in psychedelics today" [3] Strategic Initiatives - Gifford's role will focus on bridging research, regulation, and patient care to accelerate the advancement of innovative psychedelic medicines [1][3] - Clearmind is conducting clinical trials at prestigious institutions such as Yale School of Medicine and Johns Hopkins University, aiming to set industry standards for scientific rigor [3]

Core Insights - Clearmind Medicine Inc. has completed the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial for CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - Six patients have been successfully enrolled in the trial, with two at Johns Hopkins University and four at Yale School of Medicine [2] - The trial is registered on ClinicalTrials.gov under the identifier NCT05913752 [4] Management Commentary - The CEO of Clearmind expressed enthusiasm about reaching a key milestone in the trial and highlighted the efficient enrollment process, which was completed within an excellent timeline [4]

Core Insights - Clearmind Medicine Inc. has announced the publication of a U.S. patent application for a combination therapy involving 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, targeting binge behavior disorders [1][2] - The therapy aims to address various binge behaviors, including excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct, by leveraging MEAI's neuroplastic properties [2][3] - The company has filed a total of 13 patents related to its collaboration with SciSparc Ltd., focusing on conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including alcohol use disorder [5] - The company's intellectual property portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Strategic Goals - The CEO of Clearmind emphasized the company's mission to pioneer safe and effective treatments for binge behaviors, aiming to meet unmet needs in addiction medicine [4][8] - The combination of MEAI and PEA is positioned as a potentially safer and more effective treatment option compared to existing therapies [2][4]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in a U.S. patent application for a combination therapy targeting binge behavior disorders [1][2] - The therapy combines MEAI (5-methoxy-2-aminoindane) with N-Acylethanolamines, such as Palmitoylethanolamide (PEA), which may provide a new approach to treating various behavioral addictions [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes drug development programs based on THC and non-psychoactive cannabidiol [4] - The company is currently working on treatments for Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] Collaboration Details - The collaboration with Clearmind focuses on the potential of PEA-MEAI combinations to address conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data suggests that this combination therapy may effectively mitigate binge episodes while preserving natural reward pathways [3] Clearmind Medicine Inc. Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing novel psychedelic-derived therapeutics for health issues like alcohol use disorder [5] - The company holds a diverse intellectual property portfolio consisting of 19 patent families and 31 granted patents [5]

Core Insights - Clearmind Medicine Inc. successfully held its inaugural Annual Scientific Advisory Board (SAB) meeting, gathering eight experts in relevant fields to provide strategic guidance on the company's clinical and preclinical programs [1][2]. Group 1: Clinical Development - The SAB focused on Clearmind's lead candidate, 5-Methoxy-2-aminoindane (MEAI), which is currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD) [2]. - MEAI was highlighted for its unique pharmacological profile and promising safety data, suggesting potential advantages over emerging GLP-1 therapies, making it a potentially safe, accessible, and cost-effective treatment option [2]. - Preclinical findings indicate MEAI's potential to address not only AUD but also obesity, metabolic syndrome, and mental health challenges faced by veterans [2]. Group 2: Strategic Opportunities - The SAB explored opportunities to strengthen Clearmind's clinical development and potential partnerships, reviewing the company's robust intellectual property portfolio, which includes 31 granted patents worldwide [3]. - Insights from the SAB will guide the company's development strategy as it aims to deliver transformative psychedelic-derived therapies for global health challenges [3]. Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health problems, including alcohol use disorder [4]. - The company's intellectual property portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [5].

As filed with the Securities and Exchange Commission on September 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CLEARMIND MEDICINE INC. (Exact name of registrant as specified in its charter) British Columbia 2834 Not Applicable (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 101 ...